reason report
recap constrain capit spend weigh instrument
outlook
bottom line remain market perform view
compani still inadequ posit growth biolog
like lose share emerg standard biomolecular
analysi close tie competitor product
organ growth ep
street alreadi reduc expect china
rev impact outsiz affect instrument sale even
although china improv declin
eu still contain stage bound lead
soft even part busi includ pharma servic
contract chemistri remain somewhat stabl continu see
pressur instrument sale declin broader
 european market beyond given impact covid
top share loss compani alreadi experienc
reiter mp rate lower pt
instrument sale declin significantli due restrain capit
spend environ china instrument sale gener reflect
consum sale long-term recur
revenu flat given widespread uncertainti extent
macro slowdown covid believ research lab
increasingli cautiou capit budget addit
premium price instrument may disadvantag value-
orient brand agil a/op environ see
continu share loss instrument offer exacerb
alreadi subdu demand environ
china weak like persist nt despit increas activ
region china roughli half apac revenu
due covid disrupt drag overal revenu growth
neg territori end market soft china academ
govern experienc pressur univers shutdown
delay govern tender although china apac region
improv recent week still expect nt weak
region manag project china improv sequenti
y/i expect recoveri led pharma
industri strength pace recoveri key
factor growth trajectori
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep present ex-amort one-tim charg
pleas refer page import disclosur price chart analyst certif
manag take prudent step preserv cash flow
compani announc cost save program off-set impact
reduc demand marketplac manag identifi
cost save split opex cog occur
 stem mixtur temporari salari schedul
reduct furlough hire freez cash flow manag
target improv delay capital-expenditure project
inventori reduct revamp product schedul also
announc suspens share buy-back program
guid repurchas current
liquid
guidanc withdrawn estim revis slightli reflect
increas conservat suspend prior guidanc
organ growth given uncertainti surround
bake addit conservat organ growth estim
lower trough org growth
recov reduc revenu base coupl
increas margin pressur paus share repurchas program
reduc ep
rate water share market perform price target view
market perform given earlier sale forc realign continu impact lc-m
sale year believ steadi rise complex biomolecul bring
emerg standard includ mam multi-attribut monitor alreadi becom
standard close attach orbitrap platform vs mass spec
pose threat uptak instrument longer term attempt address via
launch bioaccord system product still remain earli take year
gain traction highli regul pharma qa/qc emerg standard rapidli gain
traction drug develop head toward stronghold qa/qc despit
lc compani core custom expect mass spec util
ramp higher regul qa/qc industry-lead empow cd softwar
also like see increas competit see empow cd chrom data system
key recur instrument consum sale biopharma qa/qc
like face increas competit chromeleon agil open lab
come time key oper technic leadership transit
mani take retir believ face number headwind multipl front
near term longer term valuat reflect competit headwind
compani increasingli face view share buy-back market
cap temporarili paus strong continu provid support stock
near-to-medium term
pt reflect ev/ebitda discount ev/ebitda
lst multipl believ busi under-perform peer group share
current trade consensu ebitda consensu tool averag believ
would warrant higher multipl sale rep reach full product help drive
lc-m growth biopharma market still believ offer premium product
potenti return growth sale rep new mass spec product challeng launch
bioaccord address meet biotherapeut need market deriv
price target appli low-singl digit discount averag ev/ebitda multipl
compris life scienc peer group
primari risk price target includ
could acceler stock repurchas help drive stock higher one could also
envis biopharma uptick drive equival revenu growth across competitor
uptick biopharmaceut fund could pose risk know market remain
fda approv process directli impact biopharma biotech compani
could continu favor older method continu domin biopharma drug
sale could continu acceler result acceler spend current
level revenu deriv biopharma uptick spend
biopharma like increas revenu
acceler global budget research could caus upsid risk forecast expand
budget govern academ fund could result higher revenu rel
estim signific academ exposur revenu ww
nih exposur less revenu pickup academ spend could
headwind rate estim increas global budget could result shift
focu strategi growth could increas oper risk
emerg market pose signific upsid risk view despit signific growth
china far acceler uptak product could impact view sudden
macroeconom chang lead increas fund fund could impact water
posit china repres compani revenu chang regul
lead easier oper china foreign compani like benefit well given
posit market
high attach rate integr part busi model despit entri high
resolut mass spec lc could continu remain demand drive sale higher
estim could continu maintain legaci high attach rate lc
system due requir technolog competit chang market
fda regul remain paramount affect adopt rate clinic diagnost
tool clinic diagnost remain major growth area futur chang
regul restrict use mass spectromet clinic diagnost laboratori could
also improv compani prospect restrict could affect growth adopt rate certain
tool regul would also increas cost complianc test purpos
good sold
interest expens incom
sg sale
 sale
oper expens sale
compani report svb leerink estim
